Celltrion's strategy focuses on developing and manufacturing biosimilars, which are generic versions of biologic drugs. Its current flagship drugs include biosimilars to Remicade, Rituxan ...

In the last month, the FDA has granted interchangeability status to additional adalimumab biosimilars.  Biosimilars with an ...

Celltrion’s strategy with its biosimilar of MSD’s Remicade (infliximab), launched in most of Europe around two years ago, was to go for two marketing authorisations and sell rights to one of ...

Doosan Group, a Korean power generation-to-heavy equipment conglomerate, has shaken up the leaderboard of the country’s ...

Teva and Celltrion’s attempt to muscle in on the multi-billion dollar US cancer and inflammatory disease drug market has hit a setback after the FDA rejected two key biosimilars because of ...

Rory McIlroy, of Northern Ireland, watches his tee shot on the 17th hole during the third round of the PGA Championship golf ...

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...

SEOUL, June 2 (Yonhap) -- South Korean stocks traded higher late Monday morning, led by gains in semiconductor shares, as ...

Starring Jung So-min, this is one of the saddest kdramas due to its exploration of the themes of childhood trauma and the guilt of human beings. The protagonists, Moo-young and Jin-kang, both have a ...

In May 2025, the FDA approved numerous biosimilars as interchangeable with Stelara® (ustekinumab) and Humira® (adalimumab), bringing the total ...

Adalta Ltd. is outlicensing all of its internal products and focusing instead on inlicensing early stage T-cell assets from Asia, mostly from China, Adalta CEO Tim Oldham told BioWorld. Dubbed its ...